PharmaLogic Development, Inc., a provider of strategic and operational services to the pharmaceutical and biomedical industries through the pharmaceutical, biologic and device development processes, today announced a new branding and logo to mark the company’s over 25 years of industry accomplishment, commitment to bringing new therapies to market, and vision for the future.
As PharmaLogic passed the quarter century mark, the company reached another major milestone: As of Q2 2017 PharmaLogic has contributed to 50 FDA product approvals and clearances.
“After 25 years as a leader in the industry, it was time for a new logo that reflects our brand identity,” said PharmaLogic President Gary D. Novack, Ph.D. “The new logo incorporates an eye, reflecting our extensive work in developing treatments for ophthalmic diseases, as well as the focused vision that enables us to serve clients with steadfast dedication. A clear vision helps PharmaLogic see through the complexities of clinical, business and regulatory considerations to move expertly and reliably toward our clients’ goals.” Dr. Novack is the author of over 250 peer-reviewed publications, and an active member and frequent presenter in professional ophthalmic organizations.
Christy L. Shaffer, Ph.D., General Partner at Hatteras Venture Partners said “I have worked with Dr. Novack for over 20 years, first as a CEO of an ophthalmology company, and now as a an investor in several ophthalmology companies. His expertise regulatory filings and strategies is quite useful for early-stage companies.”
Alan L. Robin, M.D., Professor, Ophthalmology, University of Michigan, and Associate Professor, Ophthalmology and International Health, Johns Hopkins University states “Dr. Novack is highly regarded for his scientific acumen, sound business ethics, and unmatched knowledge of regulatory strategy, – this combination has gained him global credibility by ophthalmologists and clients alike.”
Other accomplishments in PharmaLogic’s 25-year history include providing critical roles in development and approval of the first pharmacological treatment for macular degeneration, the first site-active corticosteroid, the first and second intravitreal drug delivery systems and the first neurological indications for botulinum toxins. Through thousands of projects, the company has served over 400 clients on four continents on and contributed to over 100 Investigational New Drug (IND) and Device Exemption (IDE) submissions. According to Dr. Novack, PharmaLogic’s consistent success and extensive experience have been the key to becoming a premier services provider to top specialty pharmaceutical and medical device clients.
About PharmaLogic Development, Inc.
PharmaLogic Development, Inc. delivers unique expertise at all stages of drug development and commercialization from preclinical data review to in-Market Medical Communication based on an unsurpassed track record of successful INDs, New Drug Applications (NDAs), and Agency interactions. PharmaLogic has enabled more than 400 clients on four continents to navigate the complex, risky world of product development, efficiently meeting milestones en route from early findings to approved product. For clients in ophthalmology, dermatology and neurology, the company provides full-range regulatory support services and representation, product research and development, clinical trial design and reporting, marketing and manufacturing. It has now contributed to 50 approved products and over 100 Investigational New Drug (IND) and Device Exemption (IDE) submissions. PharmaLogic serves all of its clients with principles of high ethical values, confidentiality, commitment to clients, quality service and technical expertise.
Allison Howell, Senior Account Director,
412-2281678, [email protected]